• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Hormonal Contraceptives for Women at Risk for HIV: New Guidelines

Slideshow

In new guidelines, the WHO and CDC stress that women should not be denied access to progestin-only injectables. The CDC recommendations for other hormonal contraceptive methods remain unchanged.

WHO and the CDC have issued new recomendations on progestin-only injectables in women who are at high risk for HIV infection. Highlights here.

References:

References1. World Health Organization (WHO). Can women who are at high risk of acquiring HIV, safely use hormonal contraception? http://www.who.int/reproductivehealth/topics/family_planning/hormonal-contraception-hiv/en/2. Tepper NK, Krashin JW, Curtis KM, Cox S, et al. Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection. MMWR Morb Mortal Wkly Rep. 2017 Sep 22;66(37):990-994. 3. Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS. 2016;30:2665–834. Hofmeyr GJ, Singata-Madliki M, Lawrie TA, Bergel E, Temmerman M. Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial. J Fam Plann Reprod Health Care. 2017;43:175–180.

Related Content
© 2024 MJH Life Sciences

All rights reserved.